KR900003167A - 피롤로[1,2,-a]이미다졸과 피롤로[1,2-a]피리딘유도체 및 5-리폭시게나제 경로 억제제로써의 이들의 용도 - Google Patents
피롤로[1,2,-a]이미다졸과 피롤로[1,2-a]피리딘유도체 및 5-리폭시게나제 경로 억제제로써의 이들의 용도 Download PDFInfo
- Publication number
- KR900003167A KR900003167A KR1019880011126A KR880011126A KR900003167A KR 900003167 A KR900003167 A KR 900003167A KR 1019880011126 A KR1019880011126 A KR 1019880011126A KR 880011126 A KR880011126 A KR 880011126A KR 900003167 A KR900003167 A KR 900003167A
- Authority
- KR
- South Korea
- Prior art keywords
- pyridyl
- pyrrolo
- dihydro
- imidazole
- dialkylamino
- Prior art date
Links
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 title claims abstract 5
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 title claims abstract 5
- 230000037361 pathway Effects 0.000 title claims abstract 5
- 239000003112 inhibitor Substances 0.000 title claims abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title claims 7
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical class C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 16
- 150000001875 compounds Chemical class 0.000 claims abstract 10
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 9
- 125000001424 substituent group Chemical group 0.000 claims 25
- -1 prop-2-ene-1-oxy Chemical group 0.000 claims 19
- 125000004663 dialkyl amino group Chemical group 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000001475 halogen functional group Chemical group 0.000 claims 11
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000006595 (C1-C3) alkylsulfinyl group Chemical group 0.000 claims 8
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 239000000460 chlorine Substances 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- PJTGDVLLCNMZHE-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(OCC)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 PJTGDVLLCNMZHE-UHFFFAOYSA-N 0.000 claims 2
- YAQMLZLLLUAODO-UHFFFAOYSA-N 2-(4-ethylsulfanylphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(SCC)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 YAQMLZLLLUAODO-UHFFFAOYSA-N 0.000 claims 2
- RUMVKQCGDXAUMH-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-pyridin-2-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2N=CC=CC=2)N2CCCC2=N1 RUMVKQCGDXAUMH-UHFFFAOYSA-N 0.000 claims 2
- KOYPRGGIPCTDMH-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-pyridin-3-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=NC=CC=2)N2CCCC2=N1 KOYPRGGIPCTDMH-UHFFFAOYSA-N 0.000 claims 2
- KRMOKGAZOYGDLF-UHFFFAOYSA-N 2-(4-methylsulfanylphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(SC)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 KRMOKGAZOYGDLF-UHFFFAOYSA-N 0.000 claims 2
- KSEJZTWORQXILM-UHFFFAOYSA-N 2-(4-methylsulfinylphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(S(=O)C)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 KSEJZTWORQXILM-UHFFFAOYSA-N 0.000 claims 2
- UAWYZYOYQADKCS-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 UAWYZYOYQADKCS-UHFFFAOYSA-N 0.000 claims 2
- GSKASZBRNQUVSM-UHFFFAOYSA-N 2-(4-propan-2-yloxyphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(OC(C)C)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 GSKASZBRNQUVSM-UHFFFAOYSA-N 0.000 claims 2
- VZXYNSYHHSMOAZ-UHFFFAOYSA-N 2-(4-propoxyphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(OCCC)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 VZXYNSYHHSMOAZ-UHFFFAOYSA-N 0.000 claims 2
- OPVNRUZKTLFULD-UHFFFAOYSA-N 3-(2,6-dimethylpyridin-4-yl)-2-(4-methoxyphenyl)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=C(C)N=C(C)C=2)N2CCCC2=N1 OPVNRUZKTLFULD-UHFFFAOYSA-N 0.000 claims 2
- MPUKSQRPOVULGI-UHFFFAOYSA-N 4-(3-pyridin-4-yl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 MPUKSQRPOVULGI-UHFFFAOYSA-N 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 241000125205 Anethum Species 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 125000005136 alkenylsulfinyl group Chemical group 0.000 claims 2
- 125000005108 alkenylthio group Chemical group 0.000 claims 2
- AZDBKFCSZHOSQZ-UHFFFAOYSA-N s-[4-(3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazol-2-yl)phenyl] 2,2-dimethylpropanethioate Chemical compound C1=CC(SC(=O)C(C)(C)C)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 AZDBKFCSZHOSQZ-UHFFFAOYSA-N 0.000 claims 2
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims 1
- GJURVSNUAPDFHY-UHFFFAOYSA-N 2-(4-ethylsulfinylphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(S(=O)CC)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 GJURVSNUAPDFHY-UHFFFAOYSA-N 0.000 claims 1
- GZYVBZFDOYTHTL-UHFFFAOYSA-N 2-(4-ethylsulfonylphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 GZYVBZFDOYTHTL-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- REWMNLTXCJLCGF-UHFFFAOYSA-N 3-(4-methylsulfinylphenyl)-2-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(S(=O)C)=CC=C1C1=C(C=2C=CN=CC=2)N=C2N1CCC2 REWMNLTXCJLCGF-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- YEQSHTFJUCIWNV-UHFFFAOYSA-N 4-(3-pyridin-4-yl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)benzenethiol Chemical compound C1=CC(S)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 YEQSHTFJUCIWNV-UHFFFAOYSA-N 0.000 claims 1
- PJLZDXOWFZEPCB-UHFFFAOYSA-N [4-(3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazol-2-yl)phenyl]sulfanylmethyl acetate Chemical compound C1=CC(SCOC(=O)C)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 PJLZDXOWFZEPCB-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005035 acylthio group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000002989 phenols Chemical class 0.000 claims 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 150000003573 thiols Chemical group 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- JPZBCLFQQZUXNO-UHFFFAOYSA-N tributyl-[2-(4-methoxyphenyl)-6,7-dihydro-5h-pyrrolo[1,2-a]imidazol-3-yl]stannane Chemical compound N1=C2CCCN2C([Sn](CCCC)(CCCC)CCCC)=C1C1=CC=C(OC)C=C1 JPZBCLFQQZUXNO-UHFFFAOYSA-N 0.000 claims 1
- IIOKDOJKJGCOEP-UHFFFAOYSA-N 3h-pyrrolo[1,2-a]imidazole Chemical group C1=CN2CC=NC2=C1 IIOKDOJKJGCOEP-UHFFFAOYSA-N 0.000 abstract 1
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (13)
- 다음식의 화합물이나 그것의 제약적 허용염.이식에서, 1) R 또는 R1중 하나는 알칼치환된 피리딜이며 다른 하나는; (a) 치환체가 H, 할로, 히드록시 C1-3알콕시, C1-3알킬티오, C1-4알킬, C1-3알킬설피닐, C1-3디알킬설포닐, C1-3알킬아미노, C1-3디알킬아미노, CF3, N-(C1-3알킬)-N-(C1-3알칸아미도), N-피롤리디노, N-피페리디노, 프로프-2-엔-1-옥시 또는 2,2,2-트리할로 에톡시로부터 선택되는 단일 치환된 페닐; (b) 치환체가 동일하며 할로, C1-3알콕시, C1-3알킬아미노, C1-3디알킬아미노, N-피롤리디노, N-피페리디노, 2,2,2-트리할로에톡시, 프로프-2-엔-1-옥시 또는 히드록시로부터 선택되거나 또는 이중치환체가 함께 메틸렌 디옥시 그룹을 형성하는 이중치환된 페닐; (c) 치환체가 동일하지 않으며 할로, C1-3알킬아미노, 니트로, N-(C1-3알킬)-N-(C1-3알칸아미도), C1-3디알킬아미노, 아미노, N-피롤리디노 또는 N-피페리디노로부터 각각 선택되는 이중치환된 페닐; (d) 치환체들중의 하나는 C1-3알콕시, 히드록시, 2,2,2-트리할로에톡시 또는 프로프-2-엔-1-옥시이어야 하며 다른 치환체는 할로, C1-3알킬아미노, N-(C1-3알킬)-N-(C1-3알칸아미도), C1-3디알킬아미노, 아미노, N-피롤리디노 또는 N-피페리디노로부터 자유롭게 선택되는 이중치환된 페닐; (e) 한 치환체는 C1-3알킬티오, C1-3알킬설피닐과 C1-3알킬설포닐로부터 선택되며 다른 한 치환체는 C1-3알콕시, 니트로, 할로, 아미노, C1-3알킬아미노 또는 C1-3디알킬아미노로부터 선택되는 이중 치환체된 페닐로부터 선택되며; 2) R 또는 R1중 하나는 2-피리딜이나 3-피리딜이며 다른 하나는: (a) 치환체가 C1-3알킬티오, C1-3알킬설피닐, C1-3알킬설포닐, C1-3알콕시 또는 히드록시로부터 선택되는 단일치환된 페닐; 또는 (b) 한 치환체는 C1-3알킬티오, C1-3알킬설피닐 또는 C1-3알킬설포닐로부터 선택되며 다른 하나는 C1-3알콕시, 니트로, 할로, 아미노, C1-3알킬아미노 또는 C1-3디알킬아미노로부터 선택되는 이중 치환체된 페닐로부터 선택되며; (3) R이 4-피리딜이며 R1은: (a) 치환체가 C1-3알킬티오, C1-3알킬설피닐, C1-3알킬설포닐 또는 히드록시로부터 선택되는 단일 치환된 페닐이거나; (b) 한 치환체는 C1-3알킬티오, C1-3알킬설피닐 또는 C1-3알킬설포닐로부터 선택되며 다른 하나는 C1-3알콕시, 니트로, 할로, 아미노, C1-3알킬아미노 또는 C1-3디알킬아미노로부터 선택되는 이중 치환된 페닐로부터 선택되며; 또는 4) R1이 4-피리딜이며 R이: (a) 치환체가 C1-3알킬티오, C1-3알킬설피닐, C1-3알킬설포닐, 히드록시 또는 C2-3알콕시, 또는 가지가 있거나 없는 C2-5알케닐티오 또는 C2-3알케닐설피닐로부터 선택되는 단일치환된 페닐; 또는 (b) 한 치환체는 C1-3알킬티오, C1-3알킬설피닐 또는 C1-3알킬설포닐로부터 선택되며 다른 하나는 C2-3알콕시, 니트로, 할로, 아미노, C1-3알킬아미노 또는 C1-3디알킬아미노, 또는 가지가 있거나 가지가 없는 C2-5알케닐티오 또는 C2-5알케닐설피닐로부터 선택되는 이중 치환된 페닐로부터 선택되며; 또는 5) R1이나 R중의 하나가 피리딜이거나 알킬 치환된 피리딜이며 다른 하나는 치환체가 티올[HS-], 아실티오[AC(O)S-], 디티오아실[AC(S)S-], 디알킬티오카르바밀[A2NC(O)S-], 디알킬디티오카르바밀[A2NC(S)S-], 알킬카르보닐알킬티오[AC(O)CH2S-], 카르브알콕시알킬티오[AOC(O)CH2S-], CH2가 C1-4알킬로 임의로 치환되고 A가 C1-9알킬인 아실옥시알킬티오[AC(O)CH2S-]로부터 선택되는 단일 치환 또는 이중치환된 페닐로부터 선택되며, R2,R3,R4,R5,R6,R7,R8과 R9는 H 또는 R2,R3,R4,R5,R6,R7,R8과 R9중의 하나 혹은 둘이 H나 C1-2로부터 자유롭게 선택되며; n은 0 또는 1이다.
- 2-(4-메틸티오페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸인 제1항의 화합물.
- 2-(4-메틸설피닐페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸인 제1항의 화합물.
- 2-(4-메틸설포닐페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메톡시페닐)-3-(2-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메톡시페닐)-3-(3-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메톡시페닐)-3-(2,6-디메틸-4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-히드록시페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-에톡시페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-[4-(1-프로폭시)페닐]-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-[4-(2-프로폭시)페닐]-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-에틸설피닐페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-에틸티오페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메캅토페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-트리메틸아세틸티오페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-아세틸티오페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-에틸설포닐페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 3-(4-메틸설피닐페닐)-2-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메틸설피닐페닐)-3-[4-(2-메틸)피리딜]-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-카브에톡시메틸티오페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 혹은 2-(4-아세톡시메틸티오페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸,
- 제약적으로 허용되는 담체나 희석제 및 효과적인 5-리폭시게나제 행로 억제량의 제1항의 화합물로 구성되는 제약적 조성물.
- 조성물이 비경구 투여에 적절한 투여단위 형태이고 약 50mg 내지 약 500mg의 활성 화합물로 구성되는 제5항의 조성물.
- 조성물이 경구 투여에 알맞는 투여단위 형태이고 약 100mg 내지 약 1000mg의 활성 화합물로 구성되는 제5항의 조성물.
- 조성물이 흡입이나 국소적 투여로 투여하기에 알맞은 투여단위 형태인 제5항의 조성물.
- 활성성분이, 2-(4-메틸티오페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메틸설피닐페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메틸설포닐페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메톡시페닐)-3-(2-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메톡시페닐)-3-(3-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메톡시페닐)-3-(2,6-디메틸-4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-히드록시페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-아톡시페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-[4-(1-프로폭시)페닐]-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-[4-(2-프로폭시)페닐]-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-에틸설피닐페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-에틸티오페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메캅토페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-트리메틸아세틸티오페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-아세틸설포닐페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-에틸설포페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 3-(4-메틸설피닐페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-메틸설피닐페닐)-3-[4-(2-메틸)-피리딜]-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 2-(4-카브에톡시메틸티오페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸, 혹은 2-(4-아세톡시메틸티오페닐)-3-(4-피리딜)-6,7-디히드로-[5H]-피롤로[1,2-a]이미다졸.
- 효고적인 5-리폭시게나제 행로 억제량의 제1항의 화합물을 이것을 필요로 하는 동물에 투여하는 것으로 이루어진 그 동물에서의 5-리폭시게나제 행로 매개질병을 치료하는 방법
- 다음식의 화합물이나 이것의 제약상 허용되는 염.상기식에서, n은 0이나 1이고, R2,R3,R4,R5,R6,R7,R8과 R9는 H 또는 R2,R3,R4,R5,R6,R7,R8과 R9중의 한개나 두개나 H나 C1-2알킬에서 독립적으로 선택되며; R10은 C1-4알킬이고, X는(a) 치환체가 H, 불소, 염소, C1-3알콕시, C1-4알킬, C1-3디알킬아미노, CF3, C1-3알킬아미노, N-피롤리디노, N-피페리디노, 프로프-2-엔-1-옥시나 2,2,2-트리할로에톡시에서 선택되는 단일 치환된 페닐; (b) 치환체들이 같고 불소, 염소, C1-3알콕시, C1-3디알킬아미노, N-피롤리디노, N-피페리디노, 2,2,2-트리할로에톡시, 프로프-2-엔-1-옥시에서 선택되거나, 이중 치환체들이 함께 메틸렌디옥시 그룹을 형성하는 이중 치환된 페닐; (c) 치환체들이 동일하지 않고 불소, 염소, C1-3알킬아미노, C1-3디알킬아미노, N-피롤리디노, 또는 N-피페리디노에서 독립적으로 선택되거나, (d) 치환체들중의 하나가 C1-3알콕시, 2,2,2-트리할로에톡시 또는 프로프-2-엔-1-옥시어어야 하며 다른 치환체들은 불소, 염소, C1-3알킬아미노, C1-3디알킬아미노, N-피롤리디노 또는 N-피페리디노이어야 하는 이중 치환된 페놀; (e) 피리딜이거나 알킬치환된 피리딜에서 선택된다.
- 2-(4-메톡시페닐)-6,7-디히드로-[5H]-피롤로-[1,2-a]이미다졸-3-일-트리-n-부틸틴인 제11항의 화합물.
- 다음식의 화합물이나 이것의 제약상 허용되는 염.상기식에서, n은 0이거나 1이고, R2,R3,R4,R5,R6,R7,R8과 R9는 H 또는 R2,R3,R4,R5,R6,R7,R8과 R9중의 하나나 둘은 H나 C1-2알킬에서 독립적으로 선택되면; Y1이나 Y2중의 하나는 C-(C1-8알카노일), N-(C1-8알콕시카보닐), N-(벤조일), N-(페녹시카보닐), N-(페닐아세틸), 또는 N-(벤질옥시카보닐)로 치환된 4-[1,2-디히드로-2-(C1-4알킬)]피리딜로부터 독립적으로 선택되고 다른 하나는, (a) 치환체가 H, 할로, C1-3알콕시, C1-3알킬티오, C1-4알킬, N-(C1-3알킬)-N-(C1-3알칸아미도), C1-3디알킬아미노, CF3, N-피롤리디노, N-피페리디노, 프로프-2-엔-1-옥시 또는 2,2,2-트리할로 에톡시로부터 선택되는 단일 치환된 페닐; (b) 치환체가 동일하며 할로, C1-3알콕시, C1-3디알킬아미노, N-피롤리디노, N-피페리디노, 2,2,2-트리할로에톡시나 프로프-2-엔-1-옥시로부터 선택되거나 이중 치환체들이 함께 메틸렌디옥시 그룹을 형성하는 이중 치환된 페닐; (c) 치환체들이 동일하지 않고 할로, N-(C1-3알킬)-N-(C1-3알칸아미도), C1-3디알킬아미노, N-피롤리디노, 또는 N-피페리디노로부터 독립적으로 선택되는 이중 치환된 페닐; 또는 (d) 치환체들중의 하나는 C1-3알콕시, C1-3알킬티오, 2,2,2-트리할로에톡시 또는 프로프-2-엔-1-옥시이어야 하며 다른 치환체는 할로, C1-3알킬아미노, N-(C1-3알킬)-N-(C1-3알칸아미도), C1-3디알킬아미노, N-피롤리디노 또는 N-피페리디노에서 독립적으로 선택되는 이중 치환된 페닐로부터 선택된다.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9225887A | 1987-09-02 | 1987-09-02 | |
| US092,258 | 1988-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR900003167A true KR900003167A (ko) | 1990-03-23 |
Family
ID=22232414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019880011126A KR900003167A (ko) | 1987-09-02 | 1988-08-31 | 피롤로[1,2,-a]이미다졸과 피롤로[1,2-a]피리딘유도체 및 5-리폭시게나제 경로 억제제로써의 이들의 용도 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0306300B1 (ko) |
| JP (1) | JPS6471876A (ko) |
| KR (1) | KR900003167A (ko) |
| CN (1) | CN1032011A (ko) |
| AT (1) | ATE122044T1 (ko) |
| AU (1) | AU1815092A (ko) |
| DE (1) | DE3853704D1 (ko) |
| DK (1) | DK483288A (ko) |
| FI (1) | FI884017A (ko) |
| HU (1) | HUT50475A (ko) |
| IL (1) | IL87604A0 (ko) |
| MY (1) | MY103766A (ko) |
| NO (1) | NO883882L (ko) |
| NZ (1) | NZ225967A (ko) |
| PT (1) | PT88390B (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002941A (en) * | 1985-12-12 | 1991-03-26 | Smithkline Beecham Corporation | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors |
| KR920702621A (ko) * | 1989-06-13 | 1992-10-06 | 스튜어트 알. 슈터 | 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제 |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| CN102093366B (zh) * | 2011-03-04 | 2012-11-28 | 中国医学科学院医药生物技术研究所 | 双环氨基吡唑类化合物及其在抗柯萨奇病毒中的应用 |
| US10526345B2 (en) | 2016-04-08 | 2020-01-07 | Mankind Pharma Ltd. | Compounds as GPR119 agonists |
| US10954229B2 (en) | 2016-04-08 | 2021-03-23 | Mankind Pharma Ltd. | GPR119 agonist compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4175127A (en) * | 1978-09-27 | 1979-11-20 | Smithkline Corporation | Pyridyl substituted 2,3-dihydroimidazo[2,1-b]thiazoles |
| US4186205A (en) * | 1979-01-08 | 1980-01-29 | Smithkline Corporation | 2,3-Di(4-substituted phenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazoles |
| ZW24186A1 (en) * | 1985-12-12 | 1987-07-08 | Smithkline Beckman Corp | Inhibition of the 5-lipoxygenase pathway |
-
1988
- 1988-08-29 NZ NZ225967A patent/NZ225967A/en unknown
- 1988-08-29 MY MYPI88000971A patent/MY103766A/en unknown
- 1988-08-30 IL IL87604A patent/IL87604A0/xx unknown
- 1988-08-30 DK DK483288A patent/DK483288A/da not_active Application Discontinuation
- 1988-08-30 JP JP63218235A patent/JPS6471876A/ja active Pending
- 1988-08-31 NO NO88883882A patent/NO883882L/no unknown
- 1988-08-31 HU HU884506A patent/HUT50475A/hu unknown
- 1988-08-31 KR KR1019880011126A patent/KR900003167A/ko not_active Application Discontinuation
- 1988-08-31 FI FI884017A patent/FI884017A/fi not_active Application Discontinuation
- 1988-08-31 PT PT88390A patent/PT88390B/pt not_active IP Right Cessation
- 1988-08-31 CN CN88106330A patent/CN1032011A/zh active Pending
- 1988-09-01 DE DE3853704T patent/DE3853704D1/de not_active Expired - Lifetime
- 1988-09-01 EP EP88308077A patent/EP0306300B1/en not_active Expired - Lifetime
- 1988-09-01 AT AT88308077T patent/ATE122044T1/de not_active IP Right Cessation
-
1992
- 1992-06-11 AU AU18150/92A patent/AU1815092A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1032011A (zh) | 1989-03-29 |
| DE3853704D1 (de) | 1995-06-08 |
| PT88390B (pt) | 1992-10-30 |
| HUT50475A (en) | 1990-02-28 |
| NO883882L (no) | 1989-03-03 |
| PT88390A (pt) | 1989-07-31 |
| EP0306300B1 (en) | 1995-05-03 |
| MY103766A (en) | 1993-09-30 |
| IL87604A0 (en) | 1989-01-31 |
| ATE122044T1 (de) | 1995-05-15 |
| DK483288A (da) | 1989-03-03 |
| AU621308B2 (en) | 1992-03-12 |
| FI884017A0 (fi) | 1988-08-31 |
| NZ225967A (en) | 1992-03-26 |
| DK483288D0 (da) | 1988-08-30 |
| FI884017A (fi) | 1989-03-03 |
| EP0306300A2 (en) | 1989-03-08 |
| JPS6471876A (en) | 1989-03-16 |
| AU1815092A (en) | 1992-08-27 |
| AU2174488A (en) | 1989-05-25 |
| NO883882D0 (no) | 1988-08-31 |
| EP0306300A3 (en) | 1990-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11535585B2 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| US6342487B1 (en) | Compositions containing at least one farnesyl transferase inhibitor and at least one topoisomerase inhibitor and compositions containing at least one farnesyl transferase inhibitor and at least one taxoid | |
| RU2345077C2 (ru) | ПРОИЗВОДНЫЕ ПИРИДИНО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ ИНГИБИТОРОВ KDR И FGFR | |
| RU95105587A (ru) | Оптически чистые соединения пиридинилметил сульфинил-1н-бензимидазола, их соли, способы получения, фармкомпозиция, способ лечения | |
| BR0113448A (pt) | Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase | |
| KR970705545A (ko) | 복소환 유도체 및 의약(heterocyclic derivative and medicine) | |
| AU4780599A (en) | Farnesyl protein transferase inhibitors with In Vivo radiosensitizing properties | |
| RU2006128788A (ru) | Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов | |
| RU94044677A (ru) | Трехзамещенные фенильные производные, способ получения, фармацевтическая композиция | |
| MY124055A (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| AU761603B2 (en) | Heterosubstituted pyridine derivatives as PDE 4 inhibitors | |
| BR9911590A (pt) | Pirimidinas bicìclicas e 3,4-diidropirimidinas bicìclicas como inibidores da proliferação celular | |
| JP2018048121A (ja) | キナーゼ阻害剤としての新規環置換ｎ−ピリジニルアミド | |
| WO2014130856A2 (en) | Treatment of skeletal-related disorders | |
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| CA2084290A1 (en) | Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases | |
| KR20010103566A (ko) | 양성자 펌프 억제제의 프로드러그 | |
| KR20110048585A (ko) | 키나제 억제제로서의 피콜린아미드 유도체 | |
| FR2883286B1 (fr) | NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT | |
| RU2003100504A (ru) | Органические соединения | |
| DE3781080D1 (de) | 2-substituierte-e-kondensierte(1,2,4)triazolo-(1,5-c)pyrimidine, pharmazeutische zubereitungen und ihre verwendung. | |
| KR880009984A (ko) | 아데노신 5'-카복사미드 유도체 | |
| CA3120351A1 (en) | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers | |
| CN113645964A (zh) | 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物 | |
| KR900003167A (ko) | 피롤로[1,2,-a]이미다졸과 피롤로[1,2-a]피리딘유도체 및 5-리폭시게나제 경로 억제제로써의 이들의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |